Updates on BTK Inhibitors and Multiple Sclerosis Trials - Part 2

In part two of this series, Drs. Shuvro Roy, Jiwon Oh, and Amit Bar-Or discuss the results of the FENhance 1 and 2 trials looking at fenebrutinib in relapsing MS. For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting . Read more about the Fenebrutinib Trial .